Drugs & Targets FDA approves Nubeqa for metastatic castration-sensitive prostate cancer June 06, 2025Vol.51 No.22
Drugs & Targets FDA grants priority review for sevabertinib in HER2-mutant NSCLC May 30, 2025Vol.51 No.21
Drugs & Targets Alligator Bioscience announces European orphan drug designation for HLX22 in gastric cancer May 30, 2025Vol.51 No.21
Regulatory News ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session May 23, 2025Vol.51 No.20By Jacquelyn Cobb
Cancer Policy FDA Commissioner Makary holds roundtable discussion on harms of talc May 23, 2025Vol.51 No.20By Claire Marie Porter
Cancer Policy Prasad’s stricter FDA policy for COVID-19 vaccines could limit future access May 23, 2025Vol.51 No.20By Claire Marie Porter
Drugs & Targets FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer May 23, 2025Vol.51 No.20
